How can advanced separations, inert hardware, orthogonal methods, and AI solve key challenges in reliable GLP-1 peptide analysis workflows?
|Articles|March 1, 2017
- LCGC North America-03-01-2017
- Volume 35
- Issue 3
Vol 35 No 3 LCGC North America March 2017 Regular Issue PDF
Click the title above to open the LCGC North America March 2017 regular issue, Vol 35 No 3, in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
The Use of Extraction Technologies in Food Safety Studiesover 9 years ago
Gaining Sensitivity in Environmental GC–MSover 9 years ago
Improving GC Performance Systematicallyover 9 years ago
Mushrooming Mycotoxin Problemsover 9 years ago
Market Profile: Food Testing with GC–MSAdvertisement
Related to this article
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
LCGC Blog: Building a Career Series That Goes Beyond the Surface
2
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5